Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (101-110 of 174) with videos related to

Pageof 18
Sort By:
Haematologica|December 9, 2017
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectivesFrancesca Gay, Monika Engelhardt, Evangelos Terpos, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Hemasphere|January 12, 2026
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 studyMeral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, et al.
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Haematologica|June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugsVittorio Montefusco, Francesca Gay, Stefano Spada, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Leukemia|May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Cancers|November 8, 2019
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled AnalysisFrancesca Bonello, Stefano Pulini, Stelvio Ballanti, et al.
Pageof 18

Showing results (101-110 of 174) with videos related to

Sort By:
Pageof 18
Haematologica|December 9, 2017
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectivesFrancesca Gay, Monika Engelhardt, Evangelos Terpos, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Hemasphere|January 12, 2026
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 studyMeral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, et al.
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Haematologica|June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugsVittorio Montefusco, Francesca Gay, Stefano Spada, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Leukemia|May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Cancers|November 8, 2019
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled AnalysisFrancesca Bonello, Stefano Pulini, Stelvio Ballanti, et al.
Pageof 18